Moberg Derma has announced the discontinuation of the development of Limtop, an actinic keratosis drug, as it failed to reach the predefined efficacy target in a completed phase II trial.
Moberg Derma president and CEO Peter Wolpert said the commercial potential of the project is believed to be decreased based on the completed study and thus continued investment is not justified.
"This does not affect the company's assessment for continued profitable growth during 2013," Wolpert added.
The Swedish pharmaceutical company's product portfolio includes topical products to treat skin disorders and pain under the brands Kerasal, Jointflex, Emtrix and Kaprolac.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/moberg-discontinues-actinic-keratosis-drug-development-110313
